This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

mFOLFIRI Combine With Nimotuzumab Second Line Chemotherapy for Squamous-cell Carcinoma of the Esophagus

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2011 by Shen Lin, Peking University.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Shen Lin, Peking University Identifier:
First received: November 22, 2011
Last updated: January 11, 2012
Last verified: November 2011
There are few studies about 2nd line treatment in advanced esophageal carcinoma (AEC), some showed that irinotecan may be effective. The investigators previous study has shown the efficacy and safety of paclitaxel/cisplatin as 1st line treatment, so in this phase II study, the investigators would like to observe the efficacy and safety of Nimotuzumab plus Irinotecan/5FU/leucovorin as 2nd line treatment if AEC after failure to 1st treatment of PTX/DDP.

Condition Intervention Phase
Advanced Esophageal Carcinoma Drug: mFOLFIRI+Nimotuzumab Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Shen Lin, Peking University:

Primary Outcome Measures:
  • overall survival [ Time Frame: 2 years ]
  • adverse events [ Time Frame: 2 weeks ]

Secondary Outcome Measures:
  • progression-free survival [ Time Frame: 1year ]
  • response rate [ Time Frame: 6 weeks ]
  • disease control rate [ Time Frame: 6 weeks ]

Estimated Enrollment: 40
Study Start Date: November 2011
Estimated Study Completion Date: November 2012
Estimated Primary Completion Date: November 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Nimotuzumab
irinotecan 180mg/m2,iv ,d1,LV 200 mg/m2 ,2h,d1,5-FU 400 mg/m2, iv,d1 5-FU 2400mg/m2,CIV,46h,q2w Nimotuzumab 200mg,iv,qw
Drug: mFOLFIRI+Nimotuzumab
irinotecan 180mg/m2,iv ,d1,LV 200 mg/m2 ,2h,d1,5-FU 400 mg/m2, iv,d1 5-FU 2400mg/m2,CIV,46h,q2w Nimotuzumab 200mg,iv,qw


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed esophageal squamous carcinoma,failed to 1st line treatment of paclitaxel/cisplatin
  • Age 18 to 75 years old
  • Measurable disease according to the RECIST criteria(diameter of the lesion should be more than 10mm by spiral CT or MRI, more than 20mm by common CT, the date of image should be less than 15 days before enrollment)
  • Life expectancy of ≥3 month
  • Karnofsky performance status ≥80
  • WBC>3,500/mm3, absolute neutrophil count ≥2000/mm3, platelet>100,000/mm3, Hb>9g/dl,Bilirubin level < 1.0 times ULN,Serum creatinine <1.0 times ULN,ALT and AST<2.5 times ULN ,AKP < 2.5 times ULN ,(≤5 times ULN in patients with liver metastases)(within 7 days before enrollment)
  • No sever complication, such as active gastrointestinal bleeding, perforation, jaundice, obstruction, non-cancerous fever>38℃;
  • Normal ECG/cardiac function
  • Good compliance
  • Having signed informed consent

Exclusion Criteria:

  • More than 1 Previous systemic therapy for metastatic esophageal squamous carcinoma
  • Known hypersensitivity to study drugs
  • Tumor with length≥10cm, liver metastasis covers more than 50% of liver,or lung metastasis covers more than 25% of lung
  • No measurable lesions, eg. pleural fluid and ascites
  • Only with Other previous malignancy within 5 year, except non-melanoma skin cancer
  • Heart failure or other sever organ dysfunction, eg. coronary artery disease, myocardial infarction within the last 6 months only Brain or bone metastasis
  • Chronic diarrhea
  • Mentally abnormal or disable cognition,including CNS metastasis
  • Pregnancy or lactation period
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01486992

Contact: xiaodong zhang, MD 861088196175

China, Beijing
Zhang Xiaodong Recruiting
Beijing, Beijing, China, 100142
Contact: XIAODONG ZHANG, MD    861088196175   
Sponsors and Collaborators
Peking University
  More Information

Responsible Party: Shen Lin, HEAD OF GI ONCOLOGY, Peking University Identifier: NCT01486992     History of Changes
Other Study ID Numbers: N+FOLFIRI-AEC-4
Study First Received: November 22, 2011
Last Updated: January 11, 2012

Additional relevant MeSH terms:
Esophageal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Head and Neck Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases processed this record on September 18, 2017